Multiparametric MR Imaging in the Assessment of Brain Tumors

Magnetic Resonance Imaging Clinics of North America

Volumn 24, Issue 1, 2016, Pages 87-122

  Kimura, Margareth ^a   da Cruz, L Celso Hygino ^b  

^a Centro Medico Barrashopping   (Brazil)

^b Section of Pediatric Radiology   (Brazil)

Author keywords

BOLD; Brain tumor; Diffusion tensor imaging; Diffusion weighted imaging; Perfusion; Permeability; Spectroscopy; Tractography

Indexed keywords

ANGIOGENESIS INHIBITOR; CHOLINE; LACTIC ACID; LIPID; TUMOR MARKER;

BRAIN DAMAGE; BRAIN LYMPHOMA; BRAIN TUMOR; CANCER GRADING; CANCER GROWTH; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURGERY; CHEMORADIOTHERAPY; CONTRAST ENHANCEMENT; DIFFERENTIAL DIAGNOSIS; DIFFUSION TENSOR IMAGING; DIFFUSION WEIGHTED IMAGING; DISEASE ACTIVITY; GLIOMA; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; MULTIPARAMETRIC MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OVERALL SURVIVAL; PATIENT CARE PLANNING; PATIENT MONITORING; PERFUSION WEIGHTED IMAGING; POSTOPERATIVE PERIOD; PREOPERATIVE EVALUATION; PROTON NUCLEAR MAGNETIC RESONANCE; RADIATION NECROSIS; RADIOSURGERY; REVIEW; STEREOTACTIC BIOPSY; TRACTOGRAPHY; TREATMENT RESPONSE; TUMOR LOCALIZATION; BRAIN NEOPLASMS; MAGNETIC RESONANCE ANGIOGRAPHY; METABOLISM; MOLECULAR IMAGING; MULTIMODAL IMAGING; TRENDS;

BIOMARKERS, TUMOR; BRAIN NEOPLASMS; DIFFUSION MAGNETIC RESONANCE IMAGING; DIFFUSION TENSOR IMAGING; HUMANS; MAGNETIC RESONANCE ANGIOGRAPHY; MOLECULAR IMAGING; MULTIMODAL IMAGING;

EID: 84955116941     PISSN: 10649689     EISSN: 15579786     Source Type: Journal    
DOI: 10.1016/j.mric.2015.09.001     Document Type: Review

References (112)

1. Ostrom Q.T., Gittleman H., Farah P., et al. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2006-2010. Neuro Oncol 2013, 15(2):1-56.
2. Gavrilovic I.T., Posner J.B. Brain metastases: epidemiology and pathophysiology. J Neurooncol 2005, 75:5-14.
3. Sul J., Posner J.B. Brain metastases: epidemiology and pathophysiology. Cancer Treat Res 2007, 136:1-21.
4. Biomarkers Definitions Working Group Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001, 69(3):89-95.
5. Stack J., Redmond O., Codd M., et al. Breast disease: tissue characterization with Gd-DTPA enhancement profiles. Radiology 1990, 174:491-494.
6. Flickinger F., Allison J., Sherry R., et al. Differentiation of benign from malignant breast masses by time intensity evaluation of contrast enhanced MRI. Magn Reson Imaging 1993, 11:617-620.
7. Zierler K.L. Circulation times and the theory of indicator-dilution methods for determining blood flow and volume. Handbook of physiology 1962, 585-615. Williams & Wilkins, Baltimore (MD). V.F. Hamilton (Ed.).
8. Lacerda S., Law M. Magnetic resonance perfusion and permeability imaging in brain tumors. Neuroimaging Clin N Am 2009, 19:527-557.
9. Hu L.S., Baxter L.C., Pinnaduwage D.S., et al. Optimized preload leakage correction methods to improve the diagnostic accuracy of dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging in posttreatment gliomas. AJNR Am J Neuroradiol 2010, 31(1):40-48.
10. Roberts H.C., Roberts T.P.L., Brasch R.C., et al. Quantitative measurement of microvascular permeability in human brain tumors achieved using dynamic contrast-enhanced MR imaging: correlation with histologic grade. AJNR Am J Neuroradiol 2000, 21(5):891-899.
11. Cha S., Knopp E.A., Johnson G., et al. Intracranial mass lesions: dynamic contrast-enhanced susceptibility-weighted echo-planar perfusion MR imaging. Radiology 2002, 223(1):11-29.
12. Padhani A.R., Dzik-Jurasz A. Perfusion MR imaging of extracranial tumor angiogenesis. Top Magn Reson Imaging 2004, 15(1):41-57.
13. Cha S., Yang L., Johnson G., et al. Comparison of microvascular permeability measurements, Ktrans, determined with conventional steady-state T1-weighted and first-pass T2*-weighted MR imaging methods in gliomas and meningiomas. AJNR Am J Neuroradiol 2006, 27(2):409-417.
14. Provenzale J.M., York G., Moya M.G., et al. Correlation of relative permeability and relative cerebral blood volume in high-grade cerebral neoplasms. AJR Am J Roentgenol 2006, 187:1036-1042.
15. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971, 285:1182-1186.
16. Vajkoczy P., Menger M.D. Vascular microenvironment in gliomas. J Neurooncol 2000, 50(1-2):99-108.
17. Dvorak H.F., Brown L.F., Detmar M., et al. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol 1995, 146(5):1029-1039.
18. Provenzale J.M., Wang G.R., Brenner T., et al. Comparison of permeability in high-grade and low-grade brain tumors using dynamic susceptibility contrast MR imaging. AJR Am J Roentgenol 2002, 178(3):711-716.
19. Maia A.C.M., Malheiros S.M.F., da Rocha A.J., et al. MR cerebral blood volume maps correlated with vascular endothelial growth factor expression and tumor grade in nonenhancing gliomas. AJNR Am J Neuroradiol 2005, 26(4):777-783.
20. Cha S. Perfusion MR imaging: basic principles and clinical applications. Magn Reson Imaging Clin N Am 2003, 11(3):403-413.
21. Law M., Yang S., Wang H., et al. Glioma grading: sensitivity, specificity, and predictive values of perfusion MR imaging and proton MR spectroscopic imaging compared with conventional MR imaging. AJNR Am J Neuroradiol 2003, 24(10):1989-1998.
22. Petrella J.R., Provenzale J.M. MR perfusion imaging of the brain: techniques and applications. Am J Roentgenol 2000, 175(1):207-219.
23. Sugahara T., Korogi Y., Kochi M., et al. Correlation of MR imaging-determined cerebral blood volume maps with histologic and angiographic determination of vascularity of gliomas. AJR Am J Roentgenol 1998, 171(6):1479-1486.
24. Cha S., Lupo J.M., Chen M.H. Differentiation of glioblastoma multiforme and single brain metastasis by peak height and percentage of signal intensity recovery derived from dynamic susceptibility weighted contrast-enhanced perfusion MR imaging. AJNR Am J Neuroradiol 2007, 28:1078-1084.
25. Yuh E.L., Barkovich A.J., Gupta N. Imaging of ependymomas: MRI and CT. Childs Nerv Syst 2009, 25:1203-1213. 100.
26. Liao W., Liu Y., Wang X., et al. Differentiation of primary central nervous system lymphoma and high-grade glioma with dynamic susceptibility contrast-enhanced perfusion magnetic resonance imaging. Acta Radiol 2009, 50(2):217-225.
27. Yang D., Korogi Y., Sugahara T., et al. Cerebral gliomas: prospective comparison of multivoxel 2D chemical-shift imaging proton MR spectroscopy, echoplanar perfusion and diffusion-weighted MRI. Neuroradiology 2002, 44(8):656-666.
28. Patankar T.F., Haroon H.A., Mills S.J., et al. Is volume transfer coefficient (Ktrans) related to histologic grade in human gliomas?. AJNR Am J Neuroradiol 2005, 26:2455-2465.
29. Law M., Yang S., Babb J.S., et al. Comparison of cerebral blood volume and vascular permeability from dynamic susceptibility contrast-enhanced perfusion MR imaging with glioma grade. AJNR Am J Neuroradiol 2004, 25:746-755.
30. Kerbel R.S. Tumor angiogenesis. N Engl J Med 2008, 358(19):2039-2049.
31. Jain R.K., di Tomaso E., Duda D.G., et al. Angiogenesis in brain tumours. Nat Rev Neurosci 2007, 8(8):610-622.
32. Danchaivijitr N., Waldman A.D., Tozer D.J., et al. Low grade gliomas: do changes in rCBV measurements at longitudinal perfusion-weighted MR imaging predict malignant transformation?. Radiology 2008, 247(1):170-178.
33. Barajas R.F., Hodgson J.G., Chang J.S., et al. Glioblastoma multiform regional genetic and cellular expression patterns: influence on anatomic and physiologic MR imaging. Radiology 2010, 254(2):564-576.
34. Provenzale J.M., Schmainda K. Perfusion imaging for brain tumor characterization and assessment of treatment response. Handbook of neuro-oncology neuroimaging 2008, 264-277. Elsevier, New York. H.B. Newton, F.A. Jolesz (Eds.).
35. Hygino da Cruz L.C., Rodriguez I., Domingues R.C., et al. Pseudoprogression and pseudoresponse: imaging challenges in the assessment of post treatment glioma. AJNR Am J Neuroradiol 2011, 32(11):1978-1985.
36. Sugahara T., Korogi Y., Tomiguchi S., et al. Post therapeutic intra axial brain tumor: the value of perfusion sensitive contrast-enhanced MR imaging for differentiating tumor recurrence from non neoplastic contrast-enhancing tissue. AJNR Am J Neuroradiol 2000, 21(5):901-909.
37. Cha S. Update on brain tumor imaging: from anatomy to physiology. AJNR Am J Neuroradiol 2006, 27:475-487.
38. Hu L.S., Baxter L.C., Smith K.A., et al. Relative cerebral blood volume values to differentiate high-grade glioma recurrence from posttreatment radiation effect: direct correlation between image-guided tissue histopathology and localized dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging measurements. AJNR Am J Neuroradiol 2009, 30(3):552-558.
39. Mangla R., Singh G., Ziegelitz D., et al. Changes in relative cerebral blood volume 1 month after radiation-temozolomide therapy can help predict overall survival in patients with glioblastoma. Radiology 2010, 256:575-584.
40. Batchelor T.T., Sorensen A.G., di Tomaso E., et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 2007, 11:83-95.
41. Gerstner E.R., Duda D.G., di Tomaso E., et al. VEGF inhibitors in the treatment of cerebral edema in patients with brain cancer. Nat Rev Clin Oncol 2009, 6:229-236.
42. de Groot J.F., Yung W.K. Bevacizumab and irinotecan in the treatment of recurrent malignant gliomas. Cancer J 2008, 14(5):279-285.
43. Noguchi K., Watanabe N., Nagayoshi T., et al. Role of diffusion-weighted echo-planar MRI in distinguishing between brain abscess and tumor: a preliminary report. Neuroradiology 1999, 41:171-174.
44. Mills S.J., Patankar T.A., Haroon H.A., et al. Do cerebral blood volume and contrast transfer coefficient predict prognosis in human glioma?. AJNR Am J Neuroradiol 2006, 27:853-858.
45. Cruz LC, Kimura M. Diffusion magnetic resonance imaging in brain tumors. In: Newton HB, Jolesz FA, editors. Handbook of neuro-oncology neuroimaging. 2nd edition.
46. Rumboldt A., Camacho D.L., Lake C.T., et al. Apparent diffusion coefficients for differentiation of cerebellar tumors in children. AJNR Am J Neuroradiol 2006, 27:1362-1369. 21.
47. Mills S.J., Soh C., Rose C.J., et al. Candidate biomarkers of extravascular extracellular space: a direct comparison of apparent diffusion coefficient and dynamic contrast-enhanced MR imaging derived measurement of the volume of the extravascular extracellular space in glioblastoma multiforme. AJNR Am J Neuroradiol 2010, 31:549-553. 32.
48. Gupta A., Young R.J., Karimi A., et al. Isolated diffusion restriction precedes the development of enhancing tumor in a subset of patients with glioblastoma. AJNR Am J Neuroradiol 2011, 32:1301-1306. 33.
49. Cruz L.C., Vieira I.G., Domingues R. Diffusion MR imaging: an important tool in the assessment of brain tumors. Neuroimaging Clin N Am 2011, 21(1):27-49.
50. Pope W.B., Qiao X.J., Kim H.J., et al. Apparent diffusion coefficient histogram analysis stratifies progression-free and overall survival in patients with recurrent GBM treated with bevacizumab: a multi-center study. J Neurooncol 2012, 108:491-498.
51. Hwang E.J., Cha Y., Leum Lee A., et al. Early response evaluation for recurrent high grade gliomas treated with bevacizumab: a volumetric analysis using diffusion-weighted imaging. J Neurooncol 2013, 112:427-435.
52. Chapman C.H., Nazem-Zadeh M., Lee O.E., et al. Regional variation in brain white matter diffusion index changes following chemoradiotherapy: a prospective study using tract-based spatial statistics. PLoS ONE 2013, 8(3):e57768.
53. Brunberg J.A., Chenevert T.L., McKeever P.E., et al. In vivo MR determination of water diffusion coefficients and diffusion anisotropy: Correlation with structural alteration in gliomas of the cerebral hemispheres. AJNR Am J Neuroradiol 1995, 16:361-371.
54. Schulder M., Maldjian J.A., Liu W.C., et al. Functional image-guided surgery of intracranial tumors located in or near the sensorimotor cortex. J Neurosurg 1998, 89:412-418.
55. Toh C.H., Castillo M., Wong A.M.-C., et al. Primary cerebral lymphoma and glioblastoma multiforme: differences in diffusion characteristics evaluated with diffusion tensor imaging. AJNR Am J Neuroradiol 2008, 29:471-475.
56. Guo A.C., Cummings T.J., Dash R.C., et al. Lymphomas and high-grade astrocytomas: comparison of water diffusibility and histologic characteristics. Radiology 2002, 224(1):177-183. 49.
57. Yamasaki F., Kurisu K., Satoh K., et al. Apparent diffusion coefficient of human brain tumors at MR imaging. Radiology 2005, 235:985-991.
58. Toh C.H., Chen Y.L., Hsieh T.C., et al. Glioblastoma multiforme with diffusion-weighted magnetic resonance imaging characteristics mimicking primary brain lymphoma. Case report. J Neurosurg 2006, 105:132-135. 68.
59. Baehring J.M., Bi W.L., Bannykh S., et al. Diffusion MRI in the early diagnosis of malignant glioma. J Neurooncol 2007, 82:221-225.
60. Goebell E., Paustenbach S., Vaeterlein O., et al. Low-grade and anaplastic gliomas: differences in architecture evaluated with diffusion-tensor MR imaging. Radiology 2006, 239:217-222.
61. Chen S., Ikawa F., Kurisu K., et al. Quantitative MR evaluation of intracranial epidermoid tumors by fast fluid-attenuated inversion recovery imaging and echo-planar diffusion-weighted imaging. AJNR Am J Neuroradiol 2001, 22(6):1089-1096.
62. Filippi C.G., Edgar M.A., Ulug A.M., et al. Appearance of meningiomas on diffusion-weighted images: correlation diffusion constants with histopathologic findings. AJNR Am J Neuroradiol 2001, 22:65-72.
63. Melhem E.R., Mori S., Mukundan G., et al. Diffusion tensor MR imaging of the brain and white matter tractography. AJR Am J Roentgenol 2002, 178(1):3-16.
64. Cruz L.C.H., Sorensen G.S. Diffusion tensor magnetic resonance imaging of brain tumors. Neurosurg Clin N Am 2005, 16:115-134.
65. Pierpaoli C., Jezzard P., Basser P., et al. Diffusion tensor MR imaging of the human brain. Radiology 1996, 201:637-648.
66. Sugahara T., Korogi Y., Kochi M., et al. Usefulness of diffusion-weighted MRI with echo-planar technique in the evaluation of cellularity in gliomas. J Magn Reson Imaging 1999, 9:53-60.
67. Murakami R., Hirai T., Sugahara T., et al. Grading astrocytic tumors by using apparent diffusion coefficient parameters: superiority of a one- versus two-parameter pilot method. Radiology 2009, 251:838-845. 108.
68. Lee E.J., Lee S.K., Agid R., et al. Preoperative grading of presumptive low-grade astrocytomas on MR imaging: diagnostic value of minimum apparent diffusion coefficient. AJNR Am J Neuroradiol 2008, 29:1872-1877.
69. Jellinson B.J., Field A.S., Medow J., et al. Diffusion tensor imaging of cerebral white matter: a pictorial review of physics, fiber tract anatomy, and tumor imaging patterns. AJNR Am J Neuroradiol 2004, 23:356-369.
70. Yoshiura T., Wu O., Zaheer A., et al. Highly diffusion-sensitized MRI of brain: dissociation of gray and white matter. Magn Reson Med 2001, 45:734-740.
71. Johnson P.C., Hunt S.J., Drayer B.P. Human cerebral gliomas: correlation of postmortem MR imaging and neuropathologic findings. Radiology 1989, 170:211-217.
72. Castillo M., Smith J.K., Kwock L., et al. Apparent diffusion coefficients in the evaluation of high-grade cerebral gliomas. AJNR Am J Neuroradiol 2001, 22(1):60-64.
73. Ross B.D., Chenevert T.L., Kim B., et al. Magnetic resonance imaging and spectroscopy: application to experimental neuro-oncology. Q Magn Reson Biol Med 1994, 1:89-106.
74. Moffat B.A., Chenevert T.L., Lawrence T.S., et al. Functional diffusion map: a noninvasive MRI biomarker for early stratification of clinical brain tumor response. Proc Natl Acad Sci U S A 2005, 102(15):5524-5529.
75. Figueiras R.G., Padhani A.R., Goh V.J., et al. Novel oncologic drugs: what they do and how they affect images. RadioGraphics 2011, 31:2059-2091.
76. Sorensen A.G., Batchelor T.T., Wen P.Y., et al. Response criteria for glioma. Nat Clin Pract Oncol 2008, 5(11):634-644.
77. Rieger J., Bähr O., Ronellenfitsch M.W., et al. Bevacizumab-induced diffusion restriction in patients with glioma: tumor progression or surrogate marker of hypoxia?. J Clin Oncol 2010, 28(27):e477.
78. Higano S., Yun X., Kumabe T., et al. Malignant astrocytic tumors: clinical importance of apparent diffusion coefficient in prediction of grade and prognosis. Radiology 2006, 241:839-846. 151.
79. Murakami R., Sugahara T., Nakamura H., et al. Malignant supratentorial astrocytoma treated with postoperative radiation therapy: prognostic value of pretreatment quantitative diffusion-weighted MR imaging. Radiology 2007, 243:493-499. 2011;196:71-6.
80. Michaelis T., Merboldt K.D., Bruhn H., et al. Absolute concentrations of metabolites in the adult human brain in vivo: quantification of localized proton MR spectra. Neuroradiology 1993, 187:219-227.
81. Castillo M., Smith J.K., Kwock L. Correlation of myo-inositol levels and grading of cerebral astrocytomas. AJNR Am J Neuroradiol 2000, 21:1645-1649.
82. Fan G., Sun B., Wu Z., et al. In vivo single-voxel proton MR spectroscopy in the differentiation of high-grade gliomas and solitary metastases. Clin Radiol 2004, 59(1):77-85. 35.
83. Chiang I.C., Kuo Y.T., Lu C.Y., et al. Distinction between high-grade gliomas and solitary metastases using peritumoral 3-T magnetic resonance spectroscopy, diffusion, and perfusion imagings. Neuroradiology 2004, 46(8):619-627.
84. Raybaud C., Barkovich A.J. Intracranial, orbital and neck masses of childhood. Pediatric neuroimaging 2012, 637-711. Lippincott Williams & Wilkins, Philadelphia, 63. 5th edition. A.J. Barkovich, C. Raybaud (Eds.).
85. Harris L., Davies N., MacPherson L., et al. The use of short-echo time 1H MRS for childhood cerebellar tumors prior to histopathological diagnosis. Pediatr Radiol 2007, 37:1101-1109.
86. Majós C., Aguilera C., Cos M., et al. In vivo proton magnetic resonance spectroscopy of intraventricular tumors of the brain. Eur Radiol 2009, 19:2049-2059.
87. Jouanneau E., Tovar R.A., Desuzinges C. Very late frontal relapse of medulloblastoma mimicking a meningioma in an adult. Usefulness of 1H magnetic resonance spectroscopy and diffusion-perfusion magnetic resonance imaging for preoperative diagnosis: case report. Neurosurgery 2006, 58(4):E789. 55.
88. Demir M.K., Iplikcioglu A.C., Dincer A., et al. Single voxel proton MR spectroscopy findings of typical and atypical intracranial meningiomas. Eur J Radiol 2006, 60:48-55. 37.
89. Gill S.S., Thomas D.G., Van Bruggen N., et al. Proton MR spectroscopy of intracranial tumours: in vivo and in vitro studies. J Comput Assist Tomogr 1990, 14:497-504.
90. Senft C., Hattingen E., Pilatus U., et al. Diagnostic value of proton magnetic resonance spectroscopy in the noninvasive grading of solid gliomas: comparison of maximum and mean choline values. Neurosurgery 2009, 65(5):908-913.
91. Howe F.A., Barton S.J., Cudlip S.A., et al. Metabolic profiles of human brain tumors using quantitative in vivo 1H magnetic resonance spectroscopy. Magn Reson Med 2003, 49:223-232.
92. Di Costanzo A., Scarabino T., Trojsi F., et al. Multiparametric 3T MR approach to the assessment of cerebral gliomas: tumor extent and malignancy. Neuroradiology 2006, 48:622-631.
93. Ganslandt O., Stadlbauer A., Fahlbusch R., et al. Proton magnetic resonance spectroscopic imaging integrated into image-guided surgery: correlation to standard magnetic resonance imaging and tumor cell density. Neurosurgery 2005, 56:291-298. 90.
94. McKnight T.R., Von Dem Bussche M.H., Vigneron D.B., et al. Histopathological validation of a three dimensional magnetic resonance spectroscopy index as a predictor of tumor presence. J Neurosurg 2002, 97:794-802.
95. Poussaint T.Y. Pediatric brain tumors. Handbook of neuro-oncology neuroimaging 2008, 469-484. Academic Press, New York. H.B. Newton, F.A. Jolesz (Eds.).
96. Stadlbauer A., Nimsky C., Buslei R., et al. Proton magnetic resonance spectroscopic imaging in the border zone of gliomas: correlation of metabolic and histological changes at low tumor infiltration- initial results. Invest Radiol 2007, 42(4):218-230.
97. Dowling C., Bollen A.W., Noworolski S.M., et al. Preoperative proton MR spectroscopic imaging of brain tumors: correlation with histopathologic analysis of resection specimens. AJNR Am J Neuroradiol 2001, 22(4):604-612.
98. Hall W.A., Galicich W., Bergman T., et al. 3-Tesla intraoperative MR imaging for neurosurgery. J Neurooncol 2006, 77(3):297-303.
99. Saraswathy S., Crawford F.W., Lamborn K.R., et al. Evaluation of MR markers that predict survival in patients with newly diagnosed GBM prior to adjuvant therapy. J Neurooncol 2009, 91(1):69-81.
100. Smith E.A., Carlos R.C., Junck L.R., et al. Developing a clinical decision model: MR spectroscopy to differentiate between recurrent tumor and radiation change in patients with new contrast-enhancing lesions. AJR Am J Roentgenol 2009, 192:W45-W52. 119.
101. Chernov M.F., Hayashi M., Izawa M., et al. Multivoxel proton MRS for differentiation of radiation-induced necrosis and tumor recurrence after gamma knife radiosurgery for brain metastases. Brain Tumor Pathol 2006, 23:19-27.
102. Murphy P.S., Viviers L., Abson C., et al. Monitoring temozolomide treatment of low-grade glioma with proton magnetic resonance spectroscopy. Br J Cancer 2004, 90:781-786.
103. Hourani R., Brant L.J., Rizk T., et al. Can proton MR spectroscopic and perfusion imaging differentiate between neoplastic and non-neoplastic brain lesions in adults?. AJNR Am J Neuroradiol 2008, 29(2):366-372.
104. Law M. MR spectroscopy of brain tumors. Top Magn Reson Imaging 2004, 15:291-313.
105. Li X., Jin H., Lu Y., et al. Identification of MRI and 1H MRSI parameters that may predict survival for patients with malignant gliomas. NMR Biomed 2004, 17:10-20.
106. Majós C., Bruna J., Julià-Sapé M., et al. Proton MR spectroscopy provides relevant prognostic information in high-grade astrocytomas. AJNR Am J Neuroradiol 2011, 32:74-80.
107. Ramsey N.F., Sommer I.E., Rutten G.J., et al. Combined analysis of language tasks in fMRI improves assessment of hemispheric dominance for language functions in individual subjects. Neuroimage 2001, 13(4):719-733.
108. Abou-Khalil B. Methods for determination of language dominance: the Wada test and proposed noninvasive alternatives. Curr Neurol Neurosci Rep 2007, 7(6):483-490.
109. Roux F.E., Boulanouar K., Lotterie J.A., et al. Language functional magnetic resonance imaging in preoperative assessment of language areas: correlation with direct cortical stimulation. Neurosurgery 2003, 52(6):1335-1345. [discussion: 1345-7].
110. Rutten G.J., Ramsey N.F., van Rijen P.C., et al. Development of a functional magnetic resonance imaging protocol for intraoperative localization of critical temporoparietal language areas. Ann Neurol 2002, 51(3):350-360.
111. Bizzi A., Blasi V., Falini A., et al. Presurgical functional MR imaging of language and motor functions: validation with intraoperative electrocortical mapping. Radiology 2008, 248(2):579-589.
112. Tsuchiya K., Fujikawa A., Nakajima M., et al. Differentiation between solitary metastasis and high-grade gliomas by diffusion tensor imaging. Br J Radiol 2005, 78:533-537.